scholarly journals Uric acid is not associated with decline in renal function or time to renal replacement therapy initiation in a referred cohort of patients with Stage III, IV and V chronic kidney disease

2015 ◽  
Vol 30 (12) ◽  
pp. 2039-2045 ◽  
Author(s):  
Hakan Nacak ◽  
Merel van Diepen ◽  
Abdul R. Qureshi ◽  
Juan J. Carrero ◽  
Theo Stijnen ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Uric Acid ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Stage Iii ◽  
Therapy Initiation ◽  
Renal Replacement Therapy Initiation

scholarly journals Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease

Hypertension ◽  
2022 ◽  
Author(s):  
Tatsufumi Oka ◽  
Yusuke Sakaguchi ◽  
Koki Hattori ◽  
Yuta Asahina ◽  
Sachio Kajimoto ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Real World ◽  
Estimated Glomerular Filtration Rate ◽  
Mineralocorticoid Receptor Antagonist ◽  
Therapy Initiation ◽  
Renal Replacement Therapy Initiation

Background: Real-world evidence about mineralocorticoid receptor antagonist (MRA) use has been limited in chronic kidney disease, particularly regarding its association with hard renal outcomes. Methods: In this retrospective cohort study, adult chronic kidney disease outpatients referred to the department of nephrology at an academic hospital between January 2005 and December 2018 were analyzed. The main inclusion criteria were estimated glomerular filtration rate ≥10 and <60 mL/min per 1.73 m 2 and follow-up ≥90 days. The exposure of interest was MRA use, defined as the administration of spironolactone, eplerenone, or potassium canrenoate. The primary outcome was renal replacement therapy initiation, defined as the initiation of chronic hemodialysis, peritoneal dialysis, or kidney transplantation. A marginal structural model using inverse probability of weighting was applied to account for potential time-varying confounders. Results: Among a total of 3195 patients, the median age and estimated glomerular filtration rate at baseline were 66 years and 38.4 mL/min per 1.73 m 2 , respectively. During follow-up (median, 5.9 years), 770 patients received MRAs, 211 died, and 478 started renal replacement therapy. In an inverse probability of weighting-weighted pooled logistic regression model, MRA use was significantly associated with a 28%-lower rate of renal replacement therapy initiation (hazard ratio, 0.72 [95% CI, 0.53–0.98]). The association between MRA use and renal replacement therapy initiation was dose-dependent ( P for trend <0.01) and consistent across patient subgroups. The incidence of hyperkalemia (>5.5 mEq/L) was somewhat higher in MRA users but not significant (hazard ratio, 1.14 [95% CI, 0.88–1.48]). Conclusions: MRA users showed a better renal prognosis across various chronic kidney disease subgroups in a real-world chronic kidney disease population.

scholarly journals FP392FIBROBLAST GROWTH FACTOR 23 AND THE RISK OF RENAL REPLACEMENT THERAPY INITIATION IN NON-DIALYSIS CHRONIC KIDNEY DISEASE PATIENTS

2018 ◽  
Vol 33 (suppl_1) ◽  
pp. i166-i166
Author(s):  
Cristina Capusa ◽  
Ana-Maria Mehedinti ◽  
Liliana Viasu ◽  
Dana Dumitru ◽  
Corina Chiriac ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Replacement Therapy ◽  
Growth Factor ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Therapy Initiation ◽  
Renal Replacement Therapy Initiation

Renal disease

2018 ◽  
Author(s):  
Quentin Milner
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Failure ◽  
Renal Function ◽  
Acute Renal Failure ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Renal Disease ◽  
Replacement Therapy ◽  
Impaired Renal Function ◽  
Anaesthetic Management

This chapter describes the anaesthetic management of the patient with renal disease. The topics include estimation of renal function, chronic kidney disease, renal replacement therapy (including haemodialysis), acute renal failure, and the patient with a transplanted kidney. For each topic, preoperative investigation and optimization, treatment, and anaesthetic management are described. The effects of impaired renal function on the elimination of anaesthetic drugs are discussed.

Acute nephrotoxicity and neurotoxicity associated with concentrated star fruit juice consumption

2020 ◽  
Vol 13 (12) ◽  
pp. e234460
Author(s):  
Isolda Prado de Negreiros Nogueira Maduro ◽  
Alba Regina Jorge Brandão ◽  
Karla Cristina Petruccelli Israel
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Case Report ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Fruit Juice ◽  
Neurological Dysfunction ◽  
Star Fruit

Star fruit toxicity has been hugely described in patients with chronic kidney disease, either on conservative or renal replacement therapy. This is a case report of a man, without prior kidney or neurological dysfunction, who appeared to develop nephrotoxicity and neurotoxicity less than 12 hours after drinking concentrated star fruit juice (approximately 20 units of the fruit). He received timely renal replacement therapy and renal function fully recovered after discharge.

scholarly journals FP265ESTIMATION OF RENAL FUNCTION USING THE COCKROFT-GAULT FORMULA, CKD-EPI AND MDRD IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON RENAL REPLACEMENT THERAPY

2015 ◽  
Vol 30 (suppl_3) ◽  
pp. iii155-iii155
Author(s):  
Andreea Andronesi ◽  
Gener Ismail ◽  
Luminita Iliuta ◽  
Andreea Gamala ◽  
Sonia Balanica
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Gault Formula

Prevention and drug therapy in chronic kidney disease

ESC CardioMed ◽  
2018 ◽  
pp. 993-999
Author(s):  
Stephan Segerer ◽  
Harald Seeger
Keyword(s):  
Risk Factors ◽  
Chronic Kidney Disease ◽  
Renal Function ◽  
Heart Disease ◽  
Drug Therapy ◽  
Renal Replacement Therapy ◽  
Kidney Disease ◽  
Replacement Therapy ◽  
Vascular Risk Factors ◽  
Function Loss

Three major goals need to be addressed in the treatment of patients with chronic kidney disease: (1) progression of renal function loss needs to be inhibited by treatment of risk factors, (2) co-morbidities and vascular risk factors have to be treated, and (3) the patient must be educated about and prepared for renal replacement therapy. During the progressive loss of renal function, the treatment necessities and medication doses need to be adjusted. Therefore, the treatment of heart disease differs between patients with normal and decreased renal function.

Sign in / Sign up

Export Citation Format

Share Document